-
2
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, dewit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
-
(2004)
N Engl J Med.
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
Dewit, R.2
Berry, W.R.3
-
3
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone in hormone refractory prostate cancer
-
Petrylak D, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone in hormone refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
-
(2004)
N Engl J Med.
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.1
Tangen, C.M.2
Hussain, M.H.3
-
4
-
-
38349167518
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
-
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-245.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 242-245
-
-
Berthold, D.R.1
Pond, G.R.2
Soban, F.3
-
5
-
-
84883402878
-
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
-
Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24(9):2402-2408.
-
(2013)
Ann Oncol.
, vol.24
, Issue.9
, pp. 2402-2408
-
-
Bahl, A.1
Oudard, S.2
Tombal, B.3
-
6
-
-
1542574202
-
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
-
Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217-227.
-
(2004)
Am J Pathol.
, vol.164
, pp. 217-227
-
-
Holzbeierlein, J.1
Lal, P.2
LaTulippe, E.3
-
7
-
-
0842311632
-
The androgen axis in recurrent prostate cancer
-
Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440-448.
-
(2004)
Clin Cancer Res.
, vol.10
, pp. 440-448
-
-
Mohler, J.L.1
Gregory, C.W.2
Ford, O.H.3
-
8
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
9
-
-
84866948935
-
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final OS analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study
-
Fizazi K, Scher HL, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final OS analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol. 2012;13:983-992.
-
(2012)
Lancet Oncol.
, vol.13
, pp. 983-992
-
-
Fizazi, K.1
Scher, H.L.2
Molina, A.3
-
10
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HL, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
-
(2012)
N Engl J Med.
, vol.367
, pp. 1187-1197
-
-
Scher, H.L.1
Fizazi, K.2
Saad, F.3
-
11
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-148.
-
(2013)
N Engl J Med.
, vol.368
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
De Bono, J.S.3
-
12
-
-
84904871070
-
Enzalutamide in metastatic prostate cancer before chemotherapy
-
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433.
-
(2014)
N Engl J Med.
, vol.371
, pp. 424-433
-
-
Beer, T.M.1
Armstrong, A.J.2
Rathkopf, D.E.3
-
14
-
-
0024806057
-
A novel hybridoma antibody (PASE/ 4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry
-
Haines AM, Larkin SE, Richardson AP, et al. A novel hybridoma antibody (PASE/ 4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer. 1989;60:887-892.
-
(1989)
Br J Cancer.
, vol.60
, pp. 887-892
-
-
Haines, A.M.1
Larkin, S.E.2
Richardson, A.P.3
-
15
-
-
0036127901
-
Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores
-
Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117:471-477.
-
(2002)
Am J Clin Pathol.
, vol.117
, pp. 471-477
-
-
Goldstein, N.S.1
-
16
-
-
84919662329
-
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer
-
Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106:dju268.
-
(2014)
J Natl Cancer Inst.
, vol.106
, pp. dju268
-
-
Fong, L.1
Carroll, P.2
Weinberg, V.3
-
17
-
-
84858800620
-
The immune contexture in human tumours: Impact on clinical outcomes
-
Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcomes. Nat Rev Cancer. 2012;12:298-306.
-
(2012)
Nat Rev Cancer.
, vol.12
, pp. 298-306
-
-
Fridman, W.H.1
Pages, F.2
Sautes-Fridman, C.3
-
18
-
-
84929361061
-
Humoral immune response against non-targeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome
-
GuhaThakurta D, Sheikh NA, Fan LQ, et al. Humoral immune response against non-targeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015;21:3619-3630.
-
(2015)
Clin Cancer Res.
, vol.21
, pp. 3619-3630
-
-
GuhaThakurta, D.1
Sheikh, N.A.2
Fan, L.Q.3
-
19
-
-
79951848084
-
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases
-
Corbiere V, Chapiro J, Stroobant V, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011;71:1253-1262.
-
(2011)
Cancer Res.
, vol.71
, pp. 1253-1262
-
-
Corbiere, V.1
Chapiro, J.2
Stroobant, V.3
-
20
-
-
49149115482
-
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells
-
Carrasco J, Van Pel A, Neyns B, et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol. 2008;180:3585-3593.
-
(2008)
J Immunol.
, vol.180
, pp. 3585-3593
-
-
Carrasco, J.1
Van Pel, A.2
Neyns, B.3
-
21
-
-
77955066199
-
Sipuleucel-T immunotherapy for castrate-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castrate-resistant prostate cancer. N Eng J Med. 2010;363:411-422.
-
(2010)
N Eng J Med.
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
22
-
-
0025314483
-
The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells
-
Seventeer GA, Shimizu Y, Horgan KJ, et al. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immuno. 1990;144:4579-4586.
-
(1990)
J Immuno.
, vol.144
, pp. 4579-4586
-
-
Seventeer, G.A.1
Shimizu, Y.2
Horgan, K.J.3
-
23
-
-
66949136652
-
ICAM-1 signaling in endothelial cells
-
Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61:22-32.
-
(2009)
Pharmacol Rep.
, vol.61
, pp. 22-32
-
-
Lawson, C.1
Wolf, S.2
-
24
-
-
0022574146
-
Induction by IL-1 and interferon-?: Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)
-
Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL-1 and interferon-?: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol. 1986;137:245-254.
-
(1986)
J Immunol.
, vol.137
, pp. 245-254
-
-
Dustin, M.L.1
Rothlein, R.2
Bhan, A.K.3
-
25
-
-
0037318423
-
Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC
-
Vidovic D, Graddis TJ, Stepan LP, et al. Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC. Hum Immunol. 2003;64:238-244.
-
(2003)
Hum Immunol.
, vol.64
, pp. 238-244
-
-
Vidovic, D.1
Graddis, T.J.2
Stepan, L.P.3
-
26
-
-
45849146906
-
CD54 is a surrogate marker of antigen presenting cell activation
-
Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008;57:1381-1390.
-
(2008)
Cancer Immunol Immunother.
, vol.57
, pp. 1381-1390
-
-
Sheikh, N.A.1
Jones, L.A.2
-
27
-
-
0034043167
-
Priming tissue-specific cellular immunity in a phase i trial of autologous dendritic cells for prostate cancer
-
Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175-2182.
-
(2000)
Clin Cancer Res.
, vol.6
, pp. 2175-2182
-
-
Burch, P.A.1
Breen, J.K.2
Buckner, J.C.3
-
28
-
-
0034554863
-
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
-
Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
-
(2000)
J Clin Oncol.
, vol.18
, pp. 3894-3903
-
-
Small, E.J.1
Fratesi, P.2
Reese, D.M.3
-
29
-
-
3242747658
-
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial
-
Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate. 2004;60:197-204.
-
(2004)
Prostate.
, vol.60
, pp. 197-204
-
-
Burch, P.A.1
Croghan, G.A.2
Gastineau, D.A.3
-
30
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
-
31
-
-
68549135290
-
Integrated data from 2 randomized double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
-
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
-
(2009)
Cancer.
, vol.115
, pp. 3670-3679
-
-
Higano, C.S.1
Schellhammer, P.F.2
Small, E.J.3
-
32
-
-
84906307078
-
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
-
Small EJ, Higano CS, Kantoff PW, et al. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis. 2014;17:259-264.
-
(2014)
Prostate Cancer Prostatic Dis.
, vol.17
, pp. 259-264
-
-
Small, E.J.1
Higano, C.S.2
Kantoff, P.W.3
-
33
-
-
84888826025
-
The prognostic importance of metastatic site in men with metastatic castrationresistant prostate cancer
-
Pond GR, Sonpavde G, de Wit R, et al. The prognostic importance of metastatic site in men with metastatic castrationresistant prostate cancer. Eur Urol. 2014;65:3-6.
-
(2014)
Eur Urol.
, vol.65
, pp. 3-6
-
-
Pond, G.R.1
Sonpavde, G.2
De Wit, R.3
-
34
-
-
84878601468
-
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial
-
Schellhammer PF, Chodak G, Whitmore JB, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 2013;81:1297-1302.
-
(2013)
Urology.
, vol.81
, pp. 1297-1302
-
-
Schellhammer, P.F.1
Chodak, G.2
Whitmore, J.B.3
-
35
-
-
84901641673
-
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicenter, randomised, double-blind, phase 3 trial
-
Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicenter, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700-712.
-
(2014)
Lancet Oncol.
, vol.15
, pp. 700-712
-
-
Kwon, E.D.1
Drake, C.G.2
Scher, H.I.3
-
36
-
-
33745304967
-
Combination immunotherapy with prostatic acid phosphatase pulsed antigenpresenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy
-
Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigenpresenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006;107:67-74.
-
(2006)
Cancer.
, vol.107
, pp. 67-74
-
-
Rini, B.I.1
Weinberg, V.2
Fong, L.3
-
37
-
-
84880866528
-
Quality of life after sipuleucel-T therapy: Results from a randomized, double-blind study in patients with androgendependent prostate cancer
-
Beer TM, Schellhammer PF, Corman JM, et al. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgendependent prostate cancer. Urology. 2013;82:410-415.
-
(2013)
Urology.
, vol.82
, pp. 410-415
-
-
Beer, T.M.1
Schellhammer, P.F.2
Corman, J.M.3
-
38
-
-
84947027206
-
P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrateresistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC) activation
-
abstr 147
-
Beer TM, Michael Glode L, Lance R, et al. P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrateresistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: evaluation of antigen-presenting cell (APC) activation. J Clin Oncol. 2013;31(suppl 6):abstr 147.
-
(2013)
J Clin Oncol.
, vol.31
-
-
Beer, T.M.1
Michael Glode, L.2
Lance, R.3
-
39
-
-
84947037051
-
Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC)
-
abstr 171
-
Antonarakis E, Kibel AS Adams GW et al. Antigen-specific immune responses through 24 months in the STAND trial: a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC). J Clin Oncol. 2015;33(suppl 7):abstr 171.
-
(2015)
J Clin Oncol.
, vol.33
-
-
Antonarakis, E.1
Kibel, A.S.2
Adams, G.W.3
-
40
-
-
84947030695
-
Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemicallyrecurrent prostate cancer (BRPC) after local therapy failure
-
abstr 5030
-
Antonarakis ES, Kibel AS, Adams GW, et al. Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemicallyrecurrent prostate cancer (BRPC) after local therapy failure. J Clin Oncol. 2015;33(suppl):abstr 5030.
-
(2015)
J Clin Oncol.
, vol.33
-
-
Antonarakis, E.S.1
Kibel, A.S.2
Adams, G.W.3
-
41
-
-
84898742280
-
A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results
-
abstr 5016
-
Antonarakis ES, Kibel AS, Adams G, et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results. J Clin Oncol. 2013;31(suppl):abstr 5016.
-
(2013)
J Clin Oncol.
, vol.31
-
-
Antonarakis, E.S.1
Kibel, A.S.2
Adams, G.3
-
42
-
-
84947030746
-
A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data
-
abstr 5041
-
Antonarakis ES, Kibel AS, Adams GW, et al. A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): preliminary clinical data. J Clin Oncol. 2014;32(5s suppl):abstr 5041.
-
(2014)
J Clin Oncol.
, vol.32
, Issue.5
-
-
Antonarakis, E.S.1
Kibel, A.S.2
Adams, G.W.3
-
43
-
-
84942882550
-
A randomized phase II trial of sipuleucel-T with concurrent vs. Sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer
-
ublished online first
-
Small EJ, Lance RS, Gardner TA, et al. A randomized phase II trial of sipuleucel-T with concurrent vs. sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. Clin Cancer Res. 2015;published online first. doi:10. 1158/1078-0432. CCR-15-0079
-
(2015)
Clin Cancer Res
-
-
Small, E.J.1
Lance, R.S.2
Gardner, T.A.3
-
44
-
-
84947035466
-
Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
-
abstr 5040
-
Quinn DI, Drake CG, Dreicer R, et al. Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2015;33(suppl):abstr 5040.
-
(2015)
J Clin Oncol.
, vol.33
-
-
Quinn, D.I.1
Drake, C.G.2
Dreicer, R.3
-
45
-
-
84904207094
-
Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model
-
Belcaid Z, Phallen JA, Zeng J, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLos One. 2014;9: e101764.
-
(2014)
PLOS ONE
, vol.9
, pp. e101764
-
-
Belcaid, Z.1
Phallen, J.A.2
Zeng, J.3
-
46
-
-
84926525215
-
Radiation and dural checkpoint blockade activate non-redundant immune mechanisms in cancer
-
Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dural checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-377.
-
(2015)
Nature.
, vol.520
, pp. 373-377
-
-
Twyman-Saint Victor, C.1
Rech, A.J.2
Maity, A.3
-
47
-
-
12244252335
-
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
-
Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728-734.
-
(2005)
Clin Cancer Res.
, vol.11
, pp. 728-734
-
-
Demaria, S.1
Kawashima, N.2
Yang, A.M.3
-
48
-
-
84857815877
-
Immunologic correlates of the abscopal effect in a patient with melanoma
-
Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925-931.
-
(2012)
N Engl J Med.
, vol.366
, pp. 925-931
-
-
Postow, M.A.1
Callahan, M.K.2
Barker, C.A.3
-
49
-
-
70249126960
-
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
-
McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27:4047-4054.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 4047-4054
-
-
McNeel, D.G.1
Dunphy, E.J.2
Davies, J.G.3
-
50
-
-
84860337839
-
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes
-
Johnson LE, McNeel DG. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate. 2012;15:730-740.
-
(2012)
Prostate.
, vol.15
, pp. 730-740
-
-
Johnson, L.E.1
McNeel, D.G.2
-
51
-
-
33845394305
-
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
-
Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006;66:1768-1778.
-
(2006)
Prostate.
, vol.66
, pp. 1768-1778
-
-
Isaacs, J.T.1
Pili, R.2
Qian, D.Z.3
-
52
-
-
84859044056
-
S100A9 Interaction with TLR4 promotes tumor growth
-
Kallberg E, Vogl T, Liberg D, et al. S100A9 Interaction with TLR4 promotes tumor growth. PLoS One. 2012;7:e34207.
-
(2012)
PLOS ONE
, vol.7
, pp. e34207
-
-
Kallberg, E.1
Vogl, T.2
Liberg, D.3
-
53
-
-
84874342427
-
Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment
-
Isaacs JT, Antony L, Dalrymple SL, et al. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2012;73:1386-1399.
-
(2012)
Cancer Res.
, vol.73
, pp. 1386-1399
-
-
Isaacs, J.T.1
Antony, L.2
Dalrymple, S.L.3
-
54
-
-
84857397717
-
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer
-
Huber ML, Haynes L, Parker C, et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:273-279.
-
(2012)
J Natl Cancer Inst.
, vol.104
, pp. 273-279
-
-
Huber, M.L.1
Haynes, L.2
Parker, C.3
-
55
-
-
79955725583
-
Listening to provenge-what a costly cancer treatment says about future medicare policy
-
Chambers JD, Neumann PJ. Listening to provenge-what a costly cancer treatment says about future medicare policy. N Engl J Med. 2011;364:1687-1689.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1687-1689
-
-
Chambers, J.D.1
Neumann, P.J.2
-
56
-
-
84939864061
-
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
-
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Eng J Med. 2015;373:737-746.
-
(2015)
New Eng J Med.
, vol.373
, pp. 737-746
-
-
Sweeney, C.J.1
Chen, Y.H.2
Carducci, M.3
-
57
-
-
84939203500
-
Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476)
-
abstr 5001
-
James ND, Sydes MR, Mason MD, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476). J Clin Oncol. 2015;33 (suppl):abstr 5001.
-
(2015)
J Clin Oncol.
, vol.33
-
-
James, N.D.1
Sydes, M.R.2
Mason, M.D.3
-
58
-
-
77949895922
-
Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeting immunotherapy in metastatic castration-resistant prostate cancer
-
Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeting immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 1099-1105
-
-
Kantoff, P.W.1
Schuetz, T.J.2
Blumenstein, B.A.3
-
59
-
-
84872488155
-
Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
-
Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013;62:137-147.
-
(2013)
Cancer Immunol Immunother.
, vol.62
, pp. 137-147
-
-
Sheikh, N.A.1
Petrylak, D.2
Kantoff, P.W.3
-
60
-
-
84866551703
-
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients
-
Kwek SS, Dao V, Roy R, et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012;189:3759-3766.
-
(2012)
J Immunol.
, vol.189
, pp. 3759-3766
-
-
Kwek, S.S.1
Dao, V.2
Roy, R.3
-
61
-
-
84891353975
-
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: Prolongation of prostatespecific antigen doubling time
-
Noguchi M, Moriva F, Suekane S, et al. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostatespecific antigen doubling time. BMC Cancer. 2013;13:613. DOI:10. 1186/ 1471-2407-13-613.
-
(2013)
BMC Cancer.
, vol.13
, pp. 613
-
-
Noguchi, M.1
Moriva, F.2
Suekane, S.3
-
62
-
-
83955162888
-
Current vaccination strategies for prostate cancer
-
Joniau S, Abrahamsson PA, Bellmunt J, et al. Current vaccination strategies for prostate cancer. Eur Urol. 2012;61:290-306.
-
(2012)
Eur Urol.
, vol.61
, pp. 290-306
-
-
Joniau, S.1
Abrahamsson, P.A.2
Bellmunt, J.3
-
64
-
-
84874841901
-
A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer
-
abstr TPS188
-
Fizazi K, Powles T, George DJ, et al. A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. J Clin Oncol. 2011;29(suppl):abstr TPS188.
-
(2011)
J Clin Oncol.
, vol.29
-
-
Fizazi, K.1
Powles, T.2
George, D.J.3
|